News | March 12, 2022
Terran Biosciences acquires Concert’s CNS therapeutics portfolio
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
